Ann: Investor Webinar, page-17

Hi BT

Correct me if I wrong, but from memory, DMX-200 never really demonstrated efficacy yet on e-GFR, am I right? The past trial only focused on reduction in proteinuria, which is very similar to Sparsentan's primary outcomes in Phase 2. (but Sparsentan did report a stable GFR in either treatments but that was not their Phase 2 primary, which they failed in Phase 3 because the eGFR was not statistically significant in phase 3).

I am just trying to find out if DMX-200 had ever demonstrated efficacy on eGFR. I can't find it and their sample size in Phase 2 was just 7 people. I understand that there is a science explanation on how DMX-200 work, but whether it actually improves the kidney function is actually a huge question mark. Appreciate any reference / explanation from anyone as I am thinking whether to participate in the CR. Thank you